Flamel Technologies S.A.
Flamel Technologies Announces Two New Feasibility Agreements
Published in Biotech Business Week, July 6th, 2009
Flamel Technologies S.A. (NASDAQ: FLML) announced that it has entered into two new feasibility agreements to apply its Medusa® platform with two additional companies. One program is designed to deliver a controlled release of a marketed hormone; the other is a Medusa formulation of a therapeutic peptide. The Company is currently working on nineteen feasibility programs with fifteen partner companies. These products are in addition to the new product collaborations announced earlier this week.
Stephen H. Willard, Flamel Technologies' chief executive officer, commented, "With these two new agreements, we are continuing to diversify our revenue base and add additional...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
More Articles from Biotech Business Week
- American Association for Cancer Research
Green tea may affect prostate cancer progression - American Cancer Society
Caucasians are at higher risk of developing Ewing's sarcoma than other races - BioMed Central
A new take on growth factor signaling in tamoxifen resistance - BioMed Central
American elderly thrash English at 'brain training' test - BioMed Central
Larvae shun the light - BioMed Central
People think bottled water is healthy ... sort of - More from this issue of Biotech Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
